🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Dresden
Clinical trial register · Germany

Clinical Trials in Dresden, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca48 Technische Universität Dresden42 Janssen Research & Development, LLC33 Novartis Pharmaceuticals29 Merck Sharp & Dohme LLC22
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Dresden

707 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Bad Homburg, Böblingen, Dresden, Ebersberg, Essen, Hamburg, Heidelberg, Leipzig
2025-01-13
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
750
Berlin, Cologne, Dresden, Freiburg im Breisgau, Hamburg, Herne, Langenau, Ratingen
2025-01-09
Active, closed
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637Breast Cancer
DrugsAtirmociclib·Ribociclib·Abemaciclib·Palbociclib
Pfizer
Phase 3
1,035
Ravensburg, Erlangen, Dresden, Leipzig, Velbert
2025-01-06
Recruiting
Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
NCT07803848Small-cell Lung Cancer
DrugTarlatamab
AIO-Studien-gGmbH
Phase 2
57
Berlin, Dresden, Essen, Flensburg, Frankfurt, Minden, München, Stuttgart
2025-01-01
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
NCT06500702Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
DrugsBrivekimig·Frexalimab·Rilzabrutinib
Sanofi
Phase 2
84
Berlin, Dresden, Hanover
2024-12-19
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604Graves' Disease
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
240
Dresden, Munich, Schwerin, Würzburg
2024-12-17
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Jena, Lübeck, Chemnitz, Cologne, Dresden, Hamburg, Hanover, Mainz
2024-12-16
Recruiting
The PERSEVERE Study
NCT06588634Pulmonary Embolism, Pulmonary Thromboembolism
Inari Medical
Not applicable
200
Chemnitz, Dresden, Mainz, München, Regensburg
2024-12-16
Recruiting
UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
NCT06726720Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance
AstraZeneca
Observational
300
Berlin, Dresden, Frankfurt am Main, Halle, Hamburg, Hanover, Heidelberg, Kassel
2024-12-16
Recruiting
REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure
NCT06557798Aortic Valve Stenosis
The Leeds Teaching Hospitals NHS Trust
Observational
550
Bad Nauheim, Bad Oeynhausen, Berlin, Cologne, Dortmund, Dresden, Düsseldorf, Frankfurt
2024-12-12
Active, closed
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide
Amgen
Phase 3
707
Berlin, Dresden, Düsseldorf, Essen, Hamburg, Heidelberg, Jena, Lübeck
2024-12-09
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
Cologne, Dresden, Erlangen, Freiburg im Breisgau, Hamburg, Hanover, Herne, München
2024-12-04
Recruiting
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06465953Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
48
Dresden, Düsseldorf, Göttingen, Leipzig, Munich
2024-12-03
Active, closed
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)
NCT06685757Antibody-mediated Rejection
DrugFelzartamab
Biogen
Phase 3
132
Berlin, Dresden, Hamburg, Regensburg
2024-12-03
Recruiting
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06634589B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
DrugsTacabrutideg·Mosunetuzumab·Sonrotoclax·Glofitamab
BeOne Medicines
Phase 1/2
80
Dresden, Jena, Kiel, Tübingen, Ulm
2024-11-27
Recruiting
ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
NCT06611319Hip Arthroplasty, Total, Prevention of Venous Thromboembolism
DrugRivaroxaban
Prof. Stavros Konstantinides, MD
Phase 3
2,932
Kremmen, Rüsselsheim am Main, Mainz, Dresden, Berlin
2024-11-26
Active, closed
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
DrugsDocetaxel·Pembrolizumab
Genmab
Phase 3
191
Esslingen am Neckar, Heidelberg, Göttingen, Hanover, Mainz, Dresden, Halle, Großhansdorf
2024-11-25
Recruiting
Pediatric Intensive Care Transport Registry
NCT07070258Critical Care Medicine, Transportation of Patients, Pediatrics
Philipps University Marburg
Observational
1,000
Dresden, Marburg
2024-11-25
Recruiting
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
NCT06532006Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
DrugsHLX22·Trastuzumab·Capecitabine·Oxaliplatin
Shanghai Henlius Biotech
Phase 3
550
Amberg, Bielefeld, Dresden, Hamburg, Hanover, Heilbronn, Reutlingen
2024-11-22
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Berlin, Cologne, Dessau, Dresden, Freiburg im Breisgau, Greifswald, Herne, Jena
2024-11-21
Active, closed
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247Leukemia
DrugQuizartinib
Daiichi Sankyo
Phase 3
700
Alzenau in Unterfranken, Berlin, Braunschweig, Dresden, Essen, Hanover, Heidelberg, Kiel
2024-11-19
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457Metabolic Dysfunction Associated Steatohepatitis
Boehringer Ingelheim
Phase 3
1,590
Berlin, Bochum, Cologne, Dresden, Frankfurt, Heidelberg, Homburg, Landshut
2024-11-12
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
135
Heidelberg, München, Dresden, Halle
2024-10-29
Active, closed
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
NCT06602193Parkinson Disease
Denali Therapeutics Inc.
Phase 2
50
Dresden, Lübeck, Tübingen
2024-10-24
Recruiting
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
NCT06649110Healthy Volunteers, Pulmonary Arterial Hypertension
Novartis Pharmaceuticals
Phase 1/2
232
Regensburg, Dresden, Berlin, Giessen, Greifswald, Heidelberg, Homburg
2024-10-24
Recruiting
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
NCT06669117Solid Tumor, MET Alteration
Pierre Fabre Medicament
Phase 1/2
140
Cologne, Dresden
2024-10-22
Recruiting
Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
NCT06648889T-ALL
DrugsIsatuximab·Bortezomib
Goethe University
Phase 2
28
Augsburg, Berlin, Bremen, Dresden, Düsseldorf, Erlangen, Frankfurt am Main, Hamburg
2024-10-22
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
NCT06544499Primary Immune Thrombocytopenia (ITP)
DrugEfgartigimod
argenx
Phase 3
69
Dresden, Essen
2024-10-18
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
DrugsLeucovorin calcium/Levoleucovorin·Erbitux·Amivantamab·Irinotecan
Janssen Research & Development, LLC
Phase 3
1,000
Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg, Mainz
2024-10-18
Active, closed
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
NCT05888922Androgenetic Alopecia, Female Pattern Baldness
DrugMinoxidil
Industrial Farmacéutica Cantabria, S.A.
Phase 3
520
Bad Bentheim, Berlin, Bochum, Darmstadt, Dresden, Düsseldorf, Frankfurt, Freiburg im Breisgau
2024-10-17
Recruiting
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
NCT06641089Arthritis, Psoriatic
DrugsSonelokimab·Risankizumab
MoonLake Immunotherapeutics AG
Phase 3
600
Berlin, Dresden, Erlangen, Frankfurt, Hamburg, Herne, Munich, München
2024-10-15
Recruiting
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449Huntington's Disease
Alnylam Pharmaceuticals
Phase 1
66
Berlin, Bochum, Bonn, Dresden, Münster, Taufkirchen, Ulm
2024-10-14
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
Boehringer Ingelheim
Phase 3
1,800
Berlin, Bochum, Cologne, Dresden, Erlangen, Frankfurt, Heidelberg, Homburg
2024-10-14
Recruiting
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
NCT05460000Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma
North Eastern German Society of Gynaecological Oncology
Phase 2
640
Aachen, Baden-Baden, Berlin, Bonn, Cologne, Detmold, Dortmund, Dresden
2024-10-11
Active, closed
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965Prurigo Nodularis
DrugPovorcitinib
Incyte Corporation
Phase 3
346
Aachen, Buxtehude, Chemnitz, Darmstadt, Dresden, Frankfurt am Main, Göttingen, Magdeburg
2024-10-10
Active, closed
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060Episodic Migraine, Chronic Migraine
DrugCorabotase
Ipsen
Phase 2
670
Berlin, Dresden, Essen, Frankfurt, Gera, Göppingen, Greifswald, Ulm
2024-10-10
Recruiting
Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study
NCT06607302Cholangiocarcinoma
iOMEDICO AG
Observational
100
Augsburg, Bad Liebenwerda, Bad Mergentheim, Berlin, Dresden, Essen, Hanover, Hof
2024-10-08
Recruiting
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479Migraine
AbbVie
Phase 2
488
Berlin, Chemnitz, Dresden, Essen, Frankfurt am Main, Westerstede
2024-10-07
Recruiting
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
NCT06559891Hypertension
SoniVie Inc.
Not applicable
261
Dresden, Erlangen, Frankfurt, Freiburg im Breisgau, Hamburg, Herne, Homburg, Leipzig
2024-10-03
Recruiting
A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
NCT06568237Multiple System Atrophy
DrugEmrusolmin
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
350
Beelitz, Dresden, Düsseldorf, Kassel, Leipzig, Marburg, München, Münster
2024-10-02
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220Head and Neck Squamous Cell Carcinoma
DrugsPetosemtamab·Pembrolizumab
Merus B.V.
Phase 3
699
Bonn, Dortmund, Dresden, Greifswald, Hamburg, Hanover, Mannheim, München
2024-09-25
Recruiting
Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs
NCT06567015Non-small Cell Lung Cancer (NSCLC)
Pierre Fabre Medicament
Phase 1/2
171
Dresden
2024-09-17
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
DrugsLeucovorin·Irinotecan·Adrucil·Cetuximab
Eli Lilly and Company
Phase 1
630
Berlin, Dresden, Essen, München
2024-09-12
Recruiting
Bilateral Subthalamic Stimulation in PD Patients With Impulse Control Disorders - STIMPulseControl
NCT06498349Parkinson Disease, Impulse Control Disorders
University of Kiel
Not applicable
60
Cologne, Dresden, Düsseldorf, Hamburg, Kiel, Marburg, Mitte, Tübingen
2024-09-05
Recruiting
STIMPulseControl Ancillary Speech Study
NCT06561919Parkinson Disease, Impulse Control Disorder
Steffen Paschen
Not applicable
60
Cologne, Dresden, Düsseldorf, Hamburg, Kiel, Marburg, Mitte, Tübingen
2024-09-05
Active, closed
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076Plaque Psoriasis
DrugZasocitinib
Takeda
Phase 3
2,099
Blankenfelde-Mahlow, Bad Bentheim, Oldenburg, Dresden, Gera, Hamburg
2024-09-04
Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
NCT06274801Pulmonary Arterial Hypertension
DrugSeralutinib
Gossamer Bio USA, Inc.
Phase 3
330
Cologne, Dresden, Giessen, Heidelberg, Munich, München, Würzburg
2024-09-03
Active, closed
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302Lymphoma, Follicular
DrugsEndoxan·Golcadomide·Pegylated liposomal doxorubicin·Bendamustine
Celgene
Phase 2
95
Regensburg, Chemnitz, Dresden
2024-08-30
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
DrugPovetacicept
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Aachen, Berlin, Dresden, Leipzig
2024-08-30
Active, closed
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
NCT06503731Antibody-mediated Rejection
argenx
Phase 2
33
Berlin, Dresden, Hamburg
2024-08-30
Active, closed
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
NCT06625411Thyroid Eye Disease
DrugVRDN-003
Viridian Therapeutics, Inc.
Phase 3
132
Berlin, Dresden, Giessen, Göttingen
2024-08-27
Active, closed
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
NCT06625398Thyroid Eye Disease
DrugVRDN-003
Viridian Therapeutics, Inc.
Phase 3
204
Berlin, Dresden, Giessen, Göttingen
2024-08-27
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
DrugsUpadacitinib·Dupilumab
AbbVie
Phase 3
675
Erlangen, Bad Bentheim, Münster, Dresden, Berlin
2024-08-19
Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429Metastatic HER2-positive Breast Cancer
DrugsZanidatamab·Vinorelbine·Eribulin·Trastuzumab
Jazz Pharmaceuticals
Phase 3
550
Berlin, Dortmund, Dresden, München, Ulm
2024-08-13
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine
AstraZeneca
Phase 3
620
Berlin, Bonn, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2024-08-12
Active, closed
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291Hypercholesterolemia
DrugsEnlicitide·Enlicitide Decanoate
Merck Sharp & Dohme LLC
Phase 3
3,000
Essen, Dresden, Hohenmölsen, Bad Berka, Berlin
2024-08-05
Recruiting
Role of Pavlovian Mechanisms for Control Over Substance Use
NCT06701487Alcohol Use Disorder (AUD), Alcoholism, Substance Use Disorders, Cannabis Use Disorder
Technische Universität Dresden
Observational
200
Dresden
2024-08-05
Active, closed
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
NCT06534892Respiratory Syncytial Virus Infections
DrugRSVPreF3 OA vaccine
GlaxoSmithKline
Phase 3
10,212
Weinheim, Munich, Freiberg, Berlin, Cologne, Dachau, Dippoldiswalde, Dresden
2024-08-01
By invitation
A Prospective Non-interventional Observational Study to Observe Long-term Treatment and Outcomes in Pulmonary Arterial Hypertension (PAH) Patients
NCT06445673Pulmonary Arterial Hypertension
AOP Orphan Pharmaceuticals AG
Observational
110
Berlin, Dresden, Greifswald
2024-07-31
Recruiting
HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
NCT05373264ADPKD
DrugHydrochlorothiazide
University Medical Center Groningen
Phase 3
300
Berlin, Cologne, Dresden, Leipzig
2024-07-31
Active, closed
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy
NCT06440967Hot Flashes
DrugsFezolinetant·Tamoxifen
Astellas Pharma Global Development, Inc.
Phase 3
982
Essen, Bottrop, Dresden, Leipzig, Mönchengladbach, München, Münster, Wolfsburg
2024-07-31
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics
Phase 3
976
Aachen, Bad Bentheim, Berlin, Bonn, Dresden, Düsseldorf, Essen, Hamburg
2024-07-19
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin
Jazz Pharmaceuticals
Phase 3
286
Freiburg im Breisgau, Heidelberg, Tübingen, München, Frankfurt am Main, Hanover, Dresden, Lübeck
2024-07-19
Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649Metastatic Colorectal Cancer
DrugsBevacizumab-awwb·Lumakras·Mvasi·Sotorasib
Amgen
Phase 3
450
Berlin, Chemnitz, Dresden, Essen, Frankfurt am Main, Hamburg, Ludwigsburg, München
2024-07-17
Recruiting
TreatHSP Platform: Adaptive Natural History Platform for Ataxias, HSPs, and Spastic Ataxias
NCT07798674Hereditary Spastic Paraplegia, Spastic Ataxia
Heidelberg University
Observational
4,000
Bochum, Bonn, Dresden, Erlangen, Essen, Göttingen, Heidelberg, Kiel
2024-07-16
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180Advanced Melanoma
DrugsVusolimogene Oderparepvec·Relatlimab·Opdivo·Keytruda
Replimune, Inc.
Phase 3
400
Berlin, Dresden, Erfurt, Essen, Hamburg, Heidelberg, Kiel, Mainz
2024-07-11
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
136
Bad Saarow, Berlin, Dresden, Hamburg, Mannheim, München, Münster, Ulm
2024-07-09
Recruiting
PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
NCT06102057Stage III Non-small Cell Lung Cancer, Locally Advanced, Unresectable
TheraOp
Phase 2
110
Dresden, Essen, Freiburg im Breisgau, Göttingen, Homburg, Mönchengladbach, München, Oldenburg
2024-07-01
Not yet open
Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging
NCT03865277Head and Neck Squamous Cell Carcinoma
Technische Universität Dresden
Phase 2
276
Freiburg im Breisgau, Heidelberg, Mannheim, Würzburg, Dresden, Leipzig, Berlin, München
2024-07-01
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Berlin, Bochum, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hanover, Kiel
2024-06-29
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6
Boehringer Ingelheim
Phase 1/2
768
Dresden, Erlangen, Essen, Hamburg, Mannheim, Ulm
2024-06-28
Active, closed
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
NCT06118281Cardiovascular Risk, Acute Myocardial Infarction (AMI)
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
10,000
Bad Berka, Berlin, Bielefeld, Bremen, Cologne, Dachau, Dortmund, Dresden
2024-06-25
Active, closed
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
NCT06425549Moderate to Severe Plaque Psoriasis
DrugsBimekizumab·Ustekinumab
UCB Biopharma SRL
Phase 3
176
Bad Bentheim, Berlin, Bonn, Dresden, Erlangen, Frankfurt am Main, Hamburg, Kiel
2024-06-25
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
DrugCladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Ulm, Göttingen, Hanover, Bochum, Düsseldorf, Dresden, Leipzig, Lübeck
2024-06-25
Active, closed
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178Head and Neck Squamous Cell Carcinoma
DrugPetosemtamab
Merus B.V.
Phase 3
621
Berlin, Dresden, Essen, Giessen, Greifswald, Hanover, Leipzig, München
2024-06-25
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288Heart Failure
DrugsVicadrostat·Dapagliflozin
Boehringer Ingelheim
Phase 3
6,712
Aachen, Bad Friedrichshall, Berlin, Bonn, Dessau, Dresden, Erfurt, Frankfurt
2024-06-17
Recruiting
Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery
NCT06414031Surgical Blood Loss, Transfusion-dependent Anemia, Abdomen Disease
DrugTranexamic Acid
Ulrich Ronellenfitsch, MD
Phase 3
850
Dresden, Halle
2024-06-17
Recruiting
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
NCT06122584Prostate Cancer
Drug18F-PSMA-1007
ABX advanced biochemical compounds GmbH
Phase 3
380
Dresden, Düsseldorf, Gronau, Hamburg, Leipzig, München, Münster, Rostock
2024-06-13
Recruiting
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
NCT06311682Atopic Dermatitis
DrugTralokinumab
LEO Pharma
Phase 3
195
Buxtehude, Dresden, Mainz, Osnabrück, Tübingen, Wuppertal
2024-06-10
Recruiting
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297Neutropenia
X4 Pharmaceuticals
Phase 3
176
Dresden
2024-06-06
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
DrugsTarlatamab·Durvalumab
Amgen
Phase 3
563
Cologne, Dresden, Essen, Gauting, Großhansdorf, Heidelberg, Münster, Würzburg
2024-06-05
Recruiting
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
NCT06112314Advanced Melanoma
DrugsBrenetafusp·Relatlimab·Opdivo·Nivolumab
Immunocore Ltd
Phase 3
680
Berlin, Bremen, Dortmund, Dresden, Erfurt, Erlangen, Essen, Frankfurt
2024-06-05
Recruiting
Long-term Follow-up of Children Born in the PETN Studies
NCT06534307Intrauterine Growth Restriction, Pentaerithrityl Teratnitrate in Pregnancy, Long-Term Effects to Children
Jena University Hospital
Observational
228
Tübingen, Ulm, München, Hanover, Bonn, Dresden, Leipzig, Halle
2024-06-01
Recruiting
Ultra-high-caloric, Fatty Diet in ALS
NCT06280079Amyotrophic Lateral Sclerosis
University of Ulm
Not applicable
392
Aachen, Berlin, Bochum, Bonn, Dresden, Erlangen, Essen, Göttingen
2024-06-01
Recruiting
Baroloop Multicenter Trial (Baroloop MCT)
NCT06518915Hypertension, Resistant to Conventional Therapy
neuroloop GmbH
Not applicable
120
Münster, Mainz, Dresden
2024-05-22
Recruiting
Anti-viral Action Against Type 1 Diabetes Autoimmunity
NCT06452654Diabetes Mellitus, Type 1
DrugSodium Chloride Inj
Technical University of Munich
Phase 4
2,252
Munich, Hanover, Dresden
2024-05-08
Active, closed
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
NCT06356311Gastroesophageal Cancer
DrugsTrifluridine/Tipiracil·Sacituzumab tirumotecan·Irinotecan·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
450
Heidelberg, Göttingen, Dresden, Kiel, Berlin, Hamburg
2024-05-03
Not yet open
Automated Screening for Clinically Ascertained Loss of Cerebral Functions
NCT06293170Irreversible Loss of Brain Function (ILBF)
Technische Universität Dresden
Not applicable
4,800
Dresden
2024-05-01
Active, closed
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
DrugRetatrutide
Eli Lilly and Company
Phase 3
10,000
Bad Nauheim, Bad Oeynhausen, Berlin, Bremen, Dortmund, Dresden, Elsterwerda, Essen
2024-04-30
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugLebrikizumab
Eli Lilly and Company
Phase 3
510
Berlin, Dresden, Frankfurt am Main, Jena, Lübeck, Sachsen
2024-04-29
Active, closed
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
NCT06339008Perennial Allergic Rhinitis (PAR)
DrugLebrikizumab
Eli Lilly and Company
Phase 3
450
Berlin, Dresden, Frankfurt am Main, Heidelberg, Marburg, Weisbaden
2024-04-26
Recruiting
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
NCT06319820Non-Muscle Invasive Bladder Neoplasms
DrugGemcitabine
Janssen Research & Development, LLC
Phase 3
641
Berlin, Braunschweig, Cologne, Dresden, Frankfurt am Main, Hamburg, Herne, Jena
2024-04-18
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Bayreuth, Berlin, Bochum, Dresden, Düsseldorf, Essen, Giessen, Hamburg
2024-04-16
Recruiting
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652Heart Failure and Impaired Kidney Function
AstraZeneca
Phase 3
3,850
Bad Nauheim, Bechhofen, Berlin, Bernau bei Berlin, Chemnitz, Coburg, Dresden, Elsterwerda
2024-04-12
Active, closed
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
NCT06307431Renal Cell Carcinoma
DrugsIntismeran autogene·Keytruda·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
272
Stuttgart, Munich, Dresden, Jena, Berlin, Hamburg
2024-04-10
Recruiting
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06330064Recurrent or Metastatic Solid Tumors
DrugIfinatamab Deruxtecan
Daiichi Sankyo
Phase 1/2
680
Heidelberg, Heilbronn, Münster, Mainz, Dresden, Leipzig, Berlin
2024-04-10
Recruiting
Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML
NCT05904106Acute Myeloid Leukemia
DrugsGemtuzumab Ozogamicin·Azacitidine·Venetoclax
Technische Universität Dresden
Phase 2
146
Essen, Aachen, Augsburg, Chemnitz, Cologne, Dresden, Erlangen, Frankfurt am Main
2024-04-07
Active, closed
A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
NCT06200207Heart Failure, Systemic Inflammation
DrugZiltivekimab
Novo Nordisk A/S
Phase 3
680
Bremen, Dresden, Elsterwerda, Erfurt, Frankfurt, Freiburg im Breisgau, Fulda, Homburg
2024-04-01
Recruiting
Assessment of Liver Diseases Using a Deep-Learning Approach Based on Ultrasound RF-Data
NCT06317181Artificial Intelligence, Ultrasonography, Elasticity Imaging Techniques, Liver Diseases
Technische Universität Dresden
Not applicable
200
Dresden, Halle, Leipzig
2024-04-01
Not yet open
Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target)
NCT05587621ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction, LDL-cholesterol
Jena University Hospital
Not applicable
300
Jena, Berlin, Dresden, Essen, Frankfurt, Freiburg im Breisgau, Halle, Homburg
2024-04-01
Rows per page Showing 201–300 of 707
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/dresden?page=3

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 707 of those studies with a site in Dresden.

How many clinical trials are recruiting in Dresden?

356 of the 707 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 17 have not yet opened recruitment, 321 are active but closed to new participants, and 13 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.